BUSINESS WIRE - 44 Montgomery St, 39th Floor, San Francisco, CA 94104; Tel: (415) 986-4422; FAX: (415) 788-5335 - Thursday, 10 October 1996
The new patent relates to Celtrix's recombinant protein production technology for making soluble proteins in bacteria. It complements two other protein production patents, which were issued to the company last year.
"Celtrix believes that this proprietary technology provides the potential for significant advantages over other methods commonly used for the production of recombinant proteins," said Andreas Sommer, Ph.D., president and chief executive officer of Celtrix.
"Celtrix has successfully produced SomatoKine(R), its novel therapeutic composition of IGF-I and its major binding protein, BP3, using this technology as well as a variety of other proteins," Dr. Sommer said. "We believe that the versatility of this technology has broad application for the production of a wide range of protein-based pharmaceuticals."
U.S. Patent No. 5,563,046 claims protein and DNA compositions of matter as well as host cells and methods of making recombinant proteins using fusion proteins. The patent claims include a number of specified fusion partners, any linker, and any non-bacterial protein of interest."
Celtrix is a biopharmaceutical company developing novel therapeutics for seriously debilitating, degenerative conditions primarily associated with severe trauma, chronic diseases or aging.
Company programs are focused on the use of SomatoKine, a novel IGF-BP3 complex, to treat destructive metabolic processes (catabolism) in acute indications such as major surgery, organ damage/failure and traumatic injury. Potential chronic indications could include osteoporosis, chronic renal (kidney) failure, and wasting conditions associated with cancer and AIDS.
Through strategic alliances with Celtrix, The Green Cross Corporation is developing SomatoKine for the treatment of osteoporosis in Japan, and Genzyme Corporation is developing TGF-beta-2 as part of a comprehensive approach to tissue repair and the treatment of systemic disease.
--30--cmf/sf*
CONTACT: Celtrix Pharmaceuticals, Santa Clara David M. Rosen (Ph.D.), 408/988-2500
REPEATS: New York 212-752-9600 or 800-221-2462; Boston 617-236-4266 or 800-225-2030; SF 415-986-4422 or 800-227-0845; LA 310-820-9473 Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. URL: http://www.businesswire.com
Copyright (c) 1996/BUSINESS WIRE. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854.
961010
BW961010
Copyright © 1996 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .